deltatrials
Terminated PHASE3 INTERVENTIONAL 2-arm NCT02762266

Transarterial Chemoembolization Compared With Stereotactic Body Radiation Therapy or Stereotactic Ablative Radiation Therapy in Treating Patients With Residual or Recurrent Liver Cancer Undergone Initial Transarterial Chemoembolization

International Randomized Study of Transarterial Chemoembolization (TACE) Versus Stereotactic Body Radiotherapy (SBRT) / Stereotactic Ablative Radiotherapy (SABR) for Residual or Recurrent Hepatocellular Carcinoma After Initial TACE

Sponsor: National Cancer Institute (NCI)

Updated 15 times since 2017 Last updated: Mar 8, 2024 Started: Feb 27, 2016 Primary completion: Dec 31, 2022 Completion: Dec 31, 2022
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Business decision - funding

A PHASE3 clinical study on Child-Pugh Class A and Child-Pugh Class B, this trial is terminated or withdrawn. The trial is conducted by National Cancer Institute (NCI) and has accumulated 15 data snapshots since 2016. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2017 – ~Mar 2017 · 59 days · monthly snapshot~Mar 2017 – ~Jun 2018 · 15 months · monthly snapshot~Jun 2018 – ~Jan 2019 · 7 months · monthly snapshot~Jan 2019 – ~Feb 2019 · 31 days · monthly snapshot~Feb 2019 – ~May 2019 · 3 months · monthly snapshot~May 2019 – ~Jun 2019 · 31 days · monthly snapshot~Jun 2019 – ~Jun 2020 · 12 months · monthly snapshot~Jun 2020 – ~Jan 2021 · 7 months · monthly snapshot~Jan 2021 – ~Sep 2021 · 8 months · monthly snapshot~Sep 2021 – ~Sep 2022 · 12 months · monthly snapshot~Sep 2022 – ~Sep 2023 · 12 months · monthly snapshot~Sep 2023 – ~Apr 2024 · 7 months · monthly snapshot~Apr 2024 – ~Jul 2024 · 3 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

15 versions recorded
  1. Sep 2024 — Present [monthly]

    Terminated PHASE3

  2. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE3

  3. Apr 2024 — Jul 2024 [monthly]

    Terminated PHASE3

    Status: CompletedTerminated

  4. Sep 2023 — Apr 2024 [monthly]

    Completed PHASE3

    Status: Active Not RecruitingCompleted

  5. Sep 2022 — Sep 2023 [monthly]

    Active Not Recruiting PHASE3

Show 10 earlier versions
  1. Sep 2021 — Sep 2022 [monthly]

    Active Not Recruiting PHASE3

  2. Jan 2021 — Sep 2021 [monthly]

    Active Not Recruiting PHASE3

  3. Jun 2020 — Jan 2021 [monthly]

    Active Not Recruiting PHASE3

    Status: RecruitingActive Not Recruiting

  4. Jun 2019 — Jun 2020 [monthly]

    Recruiting PHASE3

  5. May 2019 — Jun 2019 [monthly]

    Recruiting PHASE3

  6. Feb 2019 — May 2019 [monthly]

    Recruiting PHASE3

  7. Jan 2019 — Feb 2019 [monthly]

    Recruiting PHASE3

  8. Jun 2018 — Jan 2019 [monthly]

    Recruiting PHASE3

  9. Mar 2017 — Jun 2018 [monthly]

    Recruiting PHASE3

    Status: Not Yet RecruitingRecruiting

  10. Jan 2017 — Mar 2017 [monthly]

    Not Yet Recruiting PHASE3

    First recorded

Feb 2016

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Cancer Institute (NCI)
  • Stanford University
Data source: Stanford University

For direct contact, visit the study record on ClinicalTrials.gov .